Literature DB >> 21490291

Lactobacillus johnsonii N6.2 stimulates the innate immune response through Toll-like receptor 9 in Caco-2 cells and increases intestinal crypt Paneth cell number in biobreeding diabetes-prone rats.

Sandra D K Kingma1, Nan Li, Frank Sun, Ricardo B Valladares, Joe Neu, Graciela L Lorca.   

Abstract

Lactobacillus johnsonii (Ljo) N6.2 has been shown to mitigate the development of type 1 diabetes when administered to diabetes-prone rats. The specific mechanisms underlying this observed response remain under investigation. The objective of this study was to assess the effect of Ljo N6.2 on mucosal inflammatory response using differentiated Caco-2 monolayers. The mRNA expression levels of CCL20, CXCL8, and CXCL10 chemokines were determined by qRT-PCR. Ljo at 10(11) CFU/L induced a strong response in all chemokines examined. To assess the specific host-signaling pathways involved, we performed RT-PCR amplification of Toll-like receptors (TLR) and nucleotide-binding oligomerization domain-like receptors. TLR7 and TLR9 expression levels were induced 4.2- and 9-fold, respectively, whereas other TLR and nucleotide-binding oligomerization domain receptors were not modified. A similar effect was observed in Caco-2 monolayers treated with Ljo cell-free extract or purified nucleic acids (NA). Increased levels of IFN type 1 and IFN regulators Stat1 and IRF7 followed the upregulation of TLR9. Activation of TLR9 was also evidenced by increased Frizzled 5 expression in Ljo-treated Caco-2 cells and an increase in the number of Paneth cells in Ljo-fed, diabetes-prone rats. These results are in agreement with the polarizing-tolerizing mechanism recently described in which the apical stimulation of TLR9 in intestinal epithelial cells leads to a higher state of immunologic alertness. Furthermore, these results suggest that live probiotics could be, in the future, replaced with select cellular components.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21490291     DOI: 10.3945/jn.110.135517

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  29 in total

Review 1.  Intestinal microbiome and lymphoma development.

Authors:  Mitsuko L Yamamoto; Robert H Schiestl
Journal:  Cancer J       Date:  2014 May-Jun       Impact factor: 3.360

Review 2.  Gut microbiota and type 1 diabetes.

Authors:  Outi Vaarala
Journal:  Rev Diabet Stud       Date:  2012-12-28

3.  Interaction of Bifidobacterium bifidum LMG13195 with HT29 cells influences regulatory-T-cell-associated chemokine receptor expression.

Authors:  Patricia López; Irene González-Rodríguez; Borja Sánchez; Patricia Ruas-Madiedo; Ana Suárez; Abelardo Margolles; Miguel Gueimonde
Journal:  Appl Environ Microbiol       Date:  2012-02-17       Impact factor: 4.792

Review 4.  Type 1 diabetes and gut microbiota: Friend or foe?

Authors:  Changyun Hu; F Susan Wong; Li Wen
Journal:  Pharmacol Res       Date:  2015-03-05       Impact factor: 7.658

5.  Intestinal epithelial cells modulate antigen-presenting cell responses to bacterial DNA.

Authors:  J L Campeau; S Y Salim; E J Albert; N Hotte; K L Madsen
Journal:  Infect Immun       Date:  2012-05-21       Impact factor: 3.441

6.  Bifidobacterium pseudocatenulatum CECT7765 promotes a TLR2-dependent anti-inflammatory response in intestinal lymphocytes from mice with cirrhosis.

Authors:  Alba Moratalla; Isabel Gómez-Hurtado; Ángela Moya-Pérez; Pedro Zapater; Gloria Peiró; José M González-Navajas; Eva Maria Gómez Del Pulgar; José Such; Yolanda Sanz; Rubén Francés
Journal:  Eur J Nutr       Date:  2015-02-06       Impact factor: 5.614

Review 7.  Probiotics and immune health.

Authors:  Fang Yan; D B Polk
Journal:  Curr Opin Gastroenterol       Date:  2011-10       Impact factor: 3.287

Review 8.  Paneth cells and necrotizing enterocolitis: a novel hypothesis for disease pathogenesis.

Authors:  Steven J McElroy; Mark A Underwood; Michael P Sherman
Journal:  Neonatology       Date:  2012-09-20       Impact factor: 4.035

9.  Intestinal bacteria modify lymphoma incidence and latency by affecting systemic inflammatory state, oxidative stress, and leukocyte genotoxicity.

Authors:  Mitsuko L Yamamoto; Irene Maier; Angeline Tilly Dang; David Berry; Jared Liu; Paul M Ruegger; Jiue-In Yang; Phillip A Soto; Laura L Presley; Ramune Reliene; Aya M Westbrook; Bo Wei; Alexander Loy; Christopher Chang; Jonathan Braun; James Borneman; Robert H Schiestl
Journal:  Cancer Res       Date:  2013-07-15       Impact factor: 12.701

10.  Lactobacillus casei Zhang Counteracts Blood-Milk Barrier Disruption and Moderates the Inflammatory Response in Escherichia coli-Induced Mastitis.

Authors:  Yuhui Zheng; Gang Liu; Wei Wang; Yajing Wang; Zhijun Cao; Hongjian Yang; Shengli Li
Journal:  Front Microbiol       Date:  2021-06-24       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.